What do systematic reviews say?

Summary of findings: low‐dose vs high‐dose PERT

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 146 participants
  Very low

Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin

The review found no eligible studies for this question.

• Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase

Summary of findings: high‐dose urate oxidase showed no clear difference in frequency of adverse events ( compared with low‐dose urate oxidase (low certainty).

• Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer 2017 · Cochrane Headline outcomes only
  RR 0.54 [0.12, 2.48]
  1 study · 29 participants
  Low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

• Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1080 participants
  Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

• Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 98 participants
  Very low